Retatrutide vs tirzepatide: triple agonist versus the current leader

Tirzepatide's GIP arm, added to GLP-1, is the going explanation for why it outperforms GLP-1-only drugs on average. Retatrutide keeps both and adds glucagon-receptor activity, which raises energy expenditure and acts directly on liver fat, in theory pushing the metabolic effect further.

More receptors is not automatically better for every person, and the glucagon arm brings its own watch-items (notably heart rate). The mechanism explains the direction of the phase 2 numbers, not a guaranteed result for any individual.

In phase 2, retatrutide's top dose produced average weight loss near 24% at 48 weeks, the highest figure reported for the class so far. Tirzepatide's SURMOUNT-1 reached about 21% at 72 weeks. On the surface, retatrutide edges ahead.

But these come from different trials, durations, and populations, so the comparison is loose. Phase 2 results tend to look their best; the real test is whether phase 3 confirms both the efficacy and the safety at scale.

Averages hide wide, overlapping individual responses, and a few points of trial-average difference rarely decide a real-world outcome. What decides it is reaching a therapeutic dose, tolerating it, and staying on it, all of which favor the drug you can actually obtain and afford.

Right now that is tirzepatide. Retatrutide may eventually raise the ceiling, but a promising phase 2 figure is not a prescription, and it is not a reason to chase unregulated versions.

Tirzepatide carries the class cautions (pancreatitis vigilance, gallbladder risk with rapid loss, the thyroid C-cell exclusion, reduced oral-contraceptive effectiveness) plus the standard GI effects during titration. Retatrutide is expected to share these, with additional heart-rate attention from the glucagon arm, pending full phase 3 characterization.

The market caution is specific to retatrutide: it is not legitimately purchasable. Anything sold under the name is unregulated gray-market chemistry with no oversight, a serious risk for a potent investigational triple agonist.

If you are choosing a treatment today, tirzepatide is the real option in this comparison, alongside the other approved incretins, and the choice among them turns on coverage, tolerability, and your history.

If retatrutide eventually matters to you, the preparation is identical: build the habits that make any of these drugs work (protein, training, tracking) on whatever you and your prescriber choose now. DoseLog carries them forward to whatever the pipeline delivers.